Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common side effects of tirzepatide are gastrointestinal — nausea, loose stools, constipation and indigestion are reported most often, particularly in the first few weeks of treatment or after a dose increase. Most people find they settle as the body adjusts, and many experience little disruption at all. These are prescription-only medicines, and a prescriber assesses your full health picture before any treatment begins. Mounjaro is the UK brand name for tirzepatide, licensed for weight management and type 2 diabetes, and its side-effect profile is documented thoroughly on the NHS tirzepatide medicines page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
For the majority of people, the side effects of tirzepatide are digestive ones. Nausea is the most commonly reported, followed by diarrhoea, constipation, vomiting, burping and indigestion. You might also notice a feeling of fullness that arrives quickly during meals, this is part of how tirzepatide works, slowing gastric emptying so your stomach empties more gradually. Fatigue and headache appear in the trial data too, though less consistently.
These effects tend to be most noticeable in the first week or two after starting the medicine or stepping up to a higher dose. Many people find they can manage them by eating smaller portions, staying well hydrated, and avoiding foods that already sit heavily. Some describe them as barely noticeable; others find the first fortnight genuinely uncomfortable before things settle. For a closer look at how the body responds in those early days, the page on what to expect from tirzepatide on day one goes into more detail.
Because tirzepatide acts on both GLP-1 and GIP receptors (the only licensed weight-loss medicine in the UK to do so) its GI profile is broadly similar to semaglutide-based treatments, though individual experiences vary. Your prescriber will talk through your own health background before recommending a starting dose.
Beyond the GI effects, people sometimes ask about tirzepatide and changes to mood, including low mood or, less often, thoughts of self-harm. These are listed as possible effects in the prescribing information; if you notice any shift in your mental wellbeing after starting treatment, speak to your prescriber or GP promptly, and contact emergency services if you are in crisis.
Injection-site reactions (redness, itching or a small lump at the site) are reported by some users and are generally mild. Rotating between the abdomen, thigh and upper arm, as recommended in the Patient Information Leaflet, helps reduce localised irritation. There is also documented trial data on eye-related changes in people with pre-existing diabetic eye disease; if that applies to you, the page covering tirzepatide and eye side effects sets out what is known.
Hair thinning after significant weight loss is another question our prescribers hear fairly often. It is usually related to the physical stress of rapid weight change rather than the medicine itself, and tends to resolve. A balanced protein intake during treatment supports this. All of these are discussed during a consultation at nume's treatment assessment (sorry, at the nume consultation) the prescriber reviews your full picture, not just your BMI.
Most side effects of tirzepatide are manageable, but some are serious and need prompt action. The MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as an infrequent but significant risk: if you develop severe stomach pain that does not ease and radiates towards your back, with or without vomiting, seek medical help the same day. Do not wait for your next scheduled appointment.
Other signs that warrant urgent attention include symptoms of a serious allergic reaction (swelling of the face or throat, difficulty breathing, a rapidly spreading rash), gallbladder problems such as sudden severe pain in the upper right abdomen, and signs of significant dehydration if vomiting or diarrhoea has been prolonged. A fast or irregular heartbeat has also been reported and should be assessed. The full list of warning signs, with clear plain-English descriptions, is in the Patient Information Leaflet included with every Mounjaro pen. If you are ever unsure, call 111 or go to your nearest urgent treatment centre.
You can report any suspected side effect (whether or not you are certain it is related to the medicine) through the MHRA's Yellow Card scheme. Reporting helps build the UK's ongoing safety picture for tirzepatide, which holds Black Triangle status precisely because that monitoring continues.
A tirzepatide prescription requires a clinical assessment, by law. At nume, a GPhC-registered Independent Prescriber reads your consultation answers on the same day, a real clinician, not an automated system. Part of that review is identifying anything in your health history that might change the benefit-risk calculation: active pancreatitis, certain bowel conditions, or medicines that interact with tirzepatide are all factors a prescriber looks at. You can read more about the clinical team behind those assessments on the our clinical team page.
Treatment starts at 2.5mg, a dose chosen specifically because it gives the body time to adjust before stepping up. The side-effect burden at this level is typically lower than at maintenance doses, which is the point. If you have questions about a specific reaction you have experienced or read about, the broader overview of Mounjaro side effects covers the medicine's profile in full, and the page on side effects from tirzepatide addresses some of the more specific questions people bring to us.
Aftercare at nume runs seven days a week, so if a side effect catches you off-guard on a Saturday morning (before the school run or after) there is someone to contact. If you'd like to discuss suitability and what to expect, speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.